Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1989 Aug 1;170(2):613–618. doi: 10.1084/jem.170.2.613

Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma

PMCID: PMC2189411  PMID: 2787832

Abstract

PBMC from 11 patients with multiple myeloma (MM) were cultured in vitro in presence of IL-3 and IL-6. After 3 d, actively proliferating immunoblast-like B cells (20-62%) were apparent. After 6 d, a population of morphologically evident plasma cells was observed (30- 50%) that expressed, in each individual case, the same light and heavy chain produced by bone marrow malignant plasma cells. We conclude that in MM the malignant plasma cell precursors are circulating and their growth and terminal differentiation are under the synergistic control of IL-3 and IL-6.

Full Text

The Full Text of this article is available as a PDF (413.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989 Mar;73(4):865–879. [PubMed] [Google Scholar]
  2. Berenson J., Wong R., Kim K., Brown N., Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood. 1987 Nov;70(5):1550–1553. [PubMed] [Google Scholar]
  3. Caligaris-Cappio F., Bergui L., Tesio L., Pizzolo G., Malavasi F., Chilosi M., Campana D., van Camp B., Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest. 1985 Sep;76(3):1243–1251. doi: 10.1172/JCI112080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caligaris-Cappio F., Schena M., Bergui L., Tesio L., Riva M., Rege-Cambrin G., Funaro A., Malavasi F. C3b receptors mediate the growth factor-induced proliferation of malignant B-chronic lymphocytic leukemia lymphocytes. Leukemia. 1987 Nov;1(11):746–752. [PubMed] [Google Scholar]
  5. Durie B. G., Grogan T. M. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood. 1985 Jul;66(1):229–232. [PubMed] [Google Scholar]
  6. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  7. Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 1988 Feb;71(2):453–456. [PubMed] [Google Scholar]
  8. Hamburger A., Salmon S. E. Primary bioassay of human myeloma stem cells. J Clin Invest. 1977 Oct;60(4):846–854. doi: 10.1172/JCI108839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9035–9039. doi: 10.1073/pnas.84.24.9035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
  11. Kubagawa H., Vogler L. B., Capra J. D., Conrad M. E., Lawton A. R., Cooper M. D. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med. 1979 Oct 1;150(4):792–807. doi: 10.1084/jem.150.4.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lynch R. G., Rohrer J. W., Odermatt B., Gebel H. M., Autry J. R., Hoover R. G. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol Rev. 1979;48:45–80. doi: 10.1111/j.1600-065x.1979.tb00298.x. [DOI] [PubMed] [Google Scholar]
  13. Malavasi F., Caligaris-Cappio F., Milanese C., Dellabona P., Richiardi P., Carbonara A. O. Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Hum Immunol. 1984 Jan;9(1):9–20. doi: 10.1016/0198-8859(84)90003-x. [DOI] [PubMed] [Google Scholar]
  14. Mellstedt H., Hammarström S., Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol. 1974 Jul;17(3):371–384. [PMC free article] [PubMed] [Google Scholar]
  15. Nordan R. P., Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science. 1986 Aug 1;233(4763):566–569. doi: 10.1126/science.3726549. [DOI] [PubMed] [Google Scholar]
  16. Palacios R., Henson G., Steinmetz M., McKearn J. P. Interleukin-3 supports growth of mouse pre-B-cell clones in vitro. Nature. 1984 May 10;309(5964):126–131. doi: 10.1038/309126a0. [DOI] [PubMed] [Google Scholar]
  17. Ruiz-Argüelles G. J., Katzmann J. A., Greipp P. R., Gonchoroff N. J., Garton J. P., Kyle R. A. Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood. 1984 Aug;64(2):352–356. [PubMed] [Google Scholar]
  18. Salmon S. E., Seligmann M. B-cell neoplasia in man. Lancet. 1974 Nov 23;2(7891):1230–1233. doi: 10.1016/s0140-6736(74)90748-x. [DOI] [PubMed] [Google Scholar]
  19. Sideras P., Palacios R. Bone marrow pro-T and pro-B lymphocyte clones express functional receptors for interleukin (IL) 3 and IL 4/BSF-1 and nonfunctional receptors for IL 2. Eur J Immunol. 1987 Feb;17(2):217–221. doi: 10.1002/eji.1830170211. [DOI] [PubMed] [Google Scholar]
  20. Uckun F. M., Gesner T. G., Song C. W., Myers D. E., Mufson A. Leukemic B-cell precursors express functional receptors for human interleukin-3. Blood. 1989 Feb;73(2):533–542. [PubMed] [Google Scholar]
  21. Van Damme J., Opdenakker G., Simpson R. J., Rubira M. R., Cayphas S., Vink A., Billiau A., Van Snick J. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med. 1987 Mar 1;165(3):914–919. doi: 10.1084/jem.165.3.914. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES